Novartis sues US government over Medicare drug price negotiation programme
05 Sep 2023
Drug Approval
Preview
Source: PMLiVE
Novartis has become the latest drugmaker to sue the US government over the Medicare drug price negotiation element of President Biden’s Inflation Reduction Act (IRA).
The lawsuit, filed in federal court in New Jersey, comes just days after the Centers for Medicare and Medicaid Services (CMS) announced the first ten prescription drugs that will be subject to pricing negotiations by the health programme.
The list includes Novartis’ top-selling heart-failure medicine Entresto (sacubitril/valsartan), which the company says is the only angiotensin receptor-neprilysin inhibitor currently approved by the US Food and Drug Administration (FDA) to treat heart failure, with around 587,000 Medicare patients taking the drug every year.
The company also outlined in a statement that, since Entresto’s 2015 approval for heart failure with reduced ejection fraction (HFrEF), it has carried out additional studies to extend the use of the drug in different heart failure indications and paediatric populations.
"Under the IRA, which discourages the research and development of additional indications for small molecule medicines by implementing price controls nine years after the first FDA approval, we may not have been able to invest in researching and developing Entresto in these additional indications, depriving patients of a meaningful treatment advance,” Novartis said.
The company added that the negotiations were “unconstitutional" because they amounted to a taking of private property and imposed punitive fines on non-compliant manufacturers.
Other drugs selected for negotiation were Bristol Myers Squibb and Pfizer’s Eliquis (apixaban), Amgen's Enbrel (etanercept), AstraZeneca's Farxiga (dapagliflozin), Merck & Co's Januvia (sitagliptin), Eli Lilly and Boehringer Ingelheim's Jardiance (empagliflozin) and Novo Nordisk's Novolog/Fiasp (insulin aspart).
Johnson & Johnson's Stelara (ustekinumab) and Xarelto (rivaroxaban) were also listed, as well as its AbbVie-partnered Imbruvica (ibrutinib).
Collectively, the drugs accounted for more than $45bn in Medicare Part D spending from June 2022 to May 2023, according to the CMS.
After the negotiation period, the new prices will be announced in September 2024 and will be effective at the beginning of 2026.
The plan is facing court challenges from other leading drugmakers and industry groups, including Merck & Co, Bristol Myers Squibb, Johnson & Johnson, Boehringer Ingelheim, AstraZeneca and the Pharmaceutical Research and Manufacturers of America.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.